Clinical Trials for Ovarian Cancer

Combination Therapy With Liposomal Doxorubicin and Withaferin A (Ashwagandha, ASWD) in Recurrent Ovarian Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with platinum-resistant or refractory recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma eligible for single-agent liposomal doxorubicin receive DOXIL 40 mg/m2 q4wk plus daily oral Ashwagandha (withaferin A–rich extract) at the phase I–selected dose. Withaferin A is a multi-target botanical agent (NF-κB inhibition, ER stress induction, cytoskeletal disruption) combined with standard DOXIL to assess safety and early efficacy; excludes prior anthracyclines/liposomal doxorubicin and significant cardiac disease (LVEF ≥55% required).

ClinicalTrials.gov ID: NCT05610735

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with newly diagnosed FIGO III–IV high-grade epithelial ovarian/fallopian tube/primary peritoneal carcinoma whose tumors express HER2 (IHC 3+/2+/1+) and who completed frontline platinum plus bevacizumab are randomized to maintenance trastuzumab deruxtecan (HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor) plus bevacizumab versus bevacizumab alone. Excludes patients with BRCA mutations or on PARP maintenance and those with significant bleeding risk or prior/current ILD/pneumonitis.

ClinicalTrials.gov ID: NCT06819007

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 As a Single Agent and in Combination with Pembrolizumab (MK-3475-D20) in Subjects with Advanced Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with advanced solid tumors or T‑cell lymphomas (including CTCL) after failure/intolerance of standard therapy, ECOG 0–1, measurable disease, and biopsy‑amenable tumors receive BI‑1808, a human IgG1 anti‑TNFR2 antibody that blocks TNF‑α/TNFR2 signaling and may deplete TNFR2+ Tregs, given IV every 3 weeks as monotherapy or combined with pembrolizumab. Excludes active CNS metastases, significant autoimmune disease, recent anticancer therapy, or active infections; expansion cohorts include ovarian cancer, melanoma, and T‑cell lymphomas.

ClinicalTrials.gov ID: NCT04752826

Phase II Study of Nab-sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with recurrent, histologically confirmed low-grade serous ovarian cancer (ECOG 0–1; measurable disease; prior MEK inhibitor allowed; ≤1 prior cytotoxic regimen; no prior mTOR/PI3K/AKT inhibitors) receive nab-sirolimus (albumin-bound mTOR inhibitor targeting PI3K/AKT/mTOR) IV plus fulvestrant (SERD) IM until progression or toxicity. Single-arm study with required pre-dose biopsy; key exclusions include significant cardiopulmonary disease, active uncontrolled infections, CNS disease needing recent steroids/RT, and strong CYP3A4 interactions.

ClinicalTrials.gov ID: NCT06494150

A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Maintenance combination of mirvetuximab soravtansine (FRα-targeted antibody–drug conjugate delivering DM4) plus olaparib (PARP inhibitor) for adult women with platinum-sensitive recurrent high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer who have CR/PR/SD after platinum and medium/high FRα expression (BRCA-mutated patients must have had prior PARP). Treatment continues until progression or toxicity; key exclusions include prior FRα-targeted therapy, CNS mets, significant ocular disease, and use of strong/moderate CYP3A modifiers.

ClinicalTrials.gov ID: NCT05887609

Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with platinum-resistant high-grade serous ovarian cancer (progression within 6 months of last platinum; ECOG 0–1; any prior lines) receive oral atovaquone monotherapy. Atovaquone, an antiprotozoal repurposed here for its STAT3 pathway inhibition, is assessed for progression-free survival with correlative biopsies/ascites and imaging to evaluate on-target effects and immune microenvironment changes.

ClinicalTrials.gov ID: NCT05998135

A Phase II Trial of Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with recurrent platinum-resistant epithelial ovarian cancer (recurrence within 6 months; ECOG 0–2) receive daily oral minoxidil monotherapy; key exclusions include recent chemo/radiation, brain mets, significant cardiac disease/heart failure, uncontrolled hypertension, and dialysis. Minoxidil, an antihypertensive that activates ATP-sensitive potassium channels via SUR2 on the Kir6.2/SUR2 complex, is being tested with exploratory correlation of efficacy to tumor Kir6/SUR expression.

ClinicalTrials.gov ID: NCT05272462

PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC, ovarian, or breast cancer receiving carboplatin-based chemotherapy who have thrombocytopenia (platelets ≤85 x 10^9/L), and randomizes them to weekly subcutaneous romiplostim—a thrombopoietin receptor agonist that stimulates platelet production—versus placebo to assess the prevention of chemotherapy dose delays or reductions.

ClinicalTrials.gov ID: NCT03937154

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: Eligible patients are adults with select advanced or metastatic solid tumors (including colorectal, cholangiocarcinoma, appendiceal, pancreatic, gastric, endometrial, triple negative breast, ovarian, or prostate cancers) who have exhausted standard therapies; phase 2 focuses on colorectal cancer. Therapy is with APL-5125, an oral CK2α kinase inhibitor targeting Wnt signaling.

ClinicalTrials.gov ID: NCT06399757

Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring KRAS G12C mutations (including pretreated NSCLC and other solid tumors), who receive a combination of the investigational KRAS G12C inhibitors RMC-6291 and RMC-6236. Both agents specifically inhibit KRAS G12C mutant protein to suppress tumor growth, and eligibility includes both KRAS G12C inhibitor–naïve and previously treated patients, excluding those with primary CNS tumors or active brain metastases.

ClinicalTrials.gov ID: NCT06128551